Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 13Phase 1 6Phase 1/2 4Phase NA 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1

Interventions

Blood Specimen Collection 104Standard of Care 79Exercise 67Radiotherapy 53Radiosurgery 48Specimen Handling 45Magnetic Resonance Spectroscopy 45Surveys and Questionnaires 44Interviews as Topic 44Practice Guidelines as Topic 43Educational Status 43Methods 41Drug Therapy 35Early Intervention, Educational 30Surgical Procedures, Operative 29Palliative Care 25Control Groups 25Biopsy 24Patient Navigation 18venetoclax 17Cisplatin 17Therapeutics 16Resistance Training 16Proton Therapy 15Magnetic Resonance Imaging 15Behavior Therapy 15Neoadjuvant Therapy 13Cognitive Behavioral Therapy 13Acupuncture Therapy 13Nutritional Status 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × Bendamustine Hydrochloride × Clear all
NCT07126678 2025-08-17

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

The First Affiliated Hospital with Nanjing Medical University

Phase NA Recruiting
15 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡